-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Nurix Therapeutics, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from Q2 2020 to Q3 2024.
- Nurix Therapeutics, Inc. Earnings Per Share, Diluted for the quarter ending August 31, 2024 was -0.67 USD/shares, a 1.47% increase year-over-year.
- Nurix Therapeutics, Inc. Earnings Per Share, Diluted for the twelve months ending August 31, 2024 was -2.91 USD/shares, a 6.59% decline year-over-year.
- Nurix Therapeutics, Inc. annual Earnings Per Share, Diluted for 2023 was -2.65 USD/shares, a 28.6% increase from 2022.
- Nurix Therapeutics, Inc. annual Earnings Per Share, Diluted for 2022 was -3.71 USD/shares, a 35.9% decline from 2021.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)